Pharmaceutical Business review

Lupin resolves Solodyn patent dispute with Medicis

Following this settlement, Lupin is now eligible for selling the generic versions of Solodyn in 45mg, 90mg, and 135mg strengths under a license from Medicis commencing November 2011, or earlier under certain conditions.

The settlement also allows Lupin to sell the generic versions of Solodyn in 65mg and 115mg strengths
under a license from Medicis effective in February 2018.

Additionally, with this settlement Lupin is also eligible for selling generic versions of Solodyn in 55mg, 80mg and 105mg strengths as per a license from Medicis effective in February 2019.